Arba Minch General Hospital | ClinicalTrials HQ

4 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Primaquine for Vivax Malaria in G6PD Intermediate and Deficient Cases.	Congenital, Hereditary, and Neonatal Diseases and Abnormalities, G6PD deficiency, Hemic and Lymphatic Diseases, Infections, Mosquito-Borne Diseases, Nutritional and Metabolic Diseases, Plasmodium vivax malaria, anemia, familial hemolytic anemia, hematologic disorder, hemolytic anemia, hereditary disease, inborn carbohydrate metabolic disorder, inborn errors of metabolism, malaria, metabolic disease, parasitic infectious disease, protozoa infectious disease, vector-borne disease	Recruiting	Phase 4	2026-03-12		NCT07468513
Study Comparing Several Drugs to Understand Which Work Against Cutaneous Leishmaniasis (CL)	Euglenozoa Infections, Infections, Skin and Connective Tissue Diseases, cutaneous leishmaniasis, leishmaniasis, parasitic infectious disease, parasitic skin disorder, protozoa infectious disease, skin disorder, skin disorder caused by infection, vector-borne disease	Not yet recruiting	Phase 3	2026-03-10		NCT07463040
A Revised Tafenoquine Dose to Improve Radical Cure for Vivax Malaria	Infections, Mosquito-Borne Diseases, Plasmodium vivax malaria, malaria, parasitic infectious disease, protozoa infectious disease, vector-borne disease	Recruiting	Phase 3	2025-07-18		NCT06148792
Antimicrobial Adjuvants to Revert the Imbalance of Skin Microbiota for Improved Outcomes of Complicated Cutaneous Leishmaniasis Treatment in Ethiopia	Euglenozoa Infections, Infections, Skin and Connective Tissue Diseases, cutaneous leishmaniasis, leishmaniasis, parasitic infectious disease, parasitic skin disorder, protozoa infectious disease, skin disorder, skin disorder caused by infection, vector-borne disease	Not yet recruiting	Phase 3	2024-11-19		NCT06695143